GSK'227, a B7-H3-Targeted Antibody-Drug Conjugate, Granted Orphan Drug Designation in Small-Cell Lung Cancer by the U.S. FDA
December 11, 2025
December 11, 2025
LONDON, England, Dec. 11 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on Dec. 10, 2025:
* * *
GSK'227, a B7-H3-targeted antibody-drug conjugate, granted Orphan Drug Designation in small-cell lung cancer by the US FDA
- Designation supported by early clinical data showing durable responses in certain types of small-cell lung cancer (SCLC)
- Extensive stage SCLC is associated with high rat . . .
* * *
GSK'227, a B7-H3-targeted antibody-drug conjugate, granted Orphan Drug Designation in small-cell lung cancer by the US FDA
- Designation supported by early clinical data showing durable responses in certain types of small-cell lung cancer (SCLC)
- Extensive stage SCLC is associated with high rat . . .